血清PGRN蛋白與癡呆認知相關(guān)性研究
發(fā)布時間：2018-08-26 07:28
【摘要】：[目的]隨著我國老年人口數(shù)目的不斷增多,阿爾茨海默病(Alzheimer's disease,AD)作為一種起病隱匿的中樞神經(jīng)退行性疾病,目前已成為全球研究的熱點。阿爾茨海默病是老年癡呆中的一種常見類型,它以漸進性記憶衰退、認知功能下降、精神、行為反常為主要臨床表現(xiàn),對老年人的日常生活帶來了極其嚴重的損害,所以早期識別、早期診斷及干預(yù)對于癡呆患者尤為重要。近年來有相關(guān)證明,顆粒蛋白前體(Progranulin,PGRN)與額顳葉癡呆、阿爾茨海默病、乳腺癌、多發(fā)性硬化、系統(tǒng)性紅斑狼瘡等多種疾病相關(guān),但該蛋白對于人阿爾茨海默病的影響卻少有研究,根據(jù)以往研究,PGRN的某些機制與阿爾茨海默病和血管性癡呆的發(fā)病相關(guān),且PGRN能穿過血腦屏障,在外周血中表達,研究發(fā)現(xiàn)PGRN可能參與AD和VD的致病,因此我們在幾種類型的癡呆患者中測量了血清PGRN蛋白的濃度,并測評了 MMSE等與認知相關(guān)的量表以探究二者之間的關(guān)聯(lián)性。[方法]選取11例阿爾茨海默病患者、20例血管性癡呆患者、24例混合性癡呆患者及55例年齡、性別相匹配的健康患者,采用酶聯(lián)免疫吸附技術(shù)(enzyme-linked immunosorbent assay,ELISA)測定其血清PGRN蛋白濃度水平,通過MMSE(Mini-mental state examination)、ADAS-cog(Alzheimer's disease assessment scale cognitive section)、日常生活能力(Activity of daily living,ADL)等量表的評定對癡呆患者記憶及認知進行評估,使用SPSS22.0(Statistical Package For Social Science,SPSS)軟件包對一般統(tǒng)計資料及所有量表資料進行統(tǒng)計分析,采用方差分析比較四組量表評分及四組血清PGRN蛋白濃度的差異,事后檢驗采用LSD-t法進行兩兩進一步比較。對四組的血清PGRN蛋白濃度與ADAS評分、ADL評分及MMSE評分各細則,對于符合正態(tài)分布的數(shù)據(jù)采用pearson相關(guān)分析,對不符合正態(tài)分布的數(shù)據(jù)采用spearson進行分析。以p0.05認為差異有統(tǒng)計學(xué)意義。[結(jié)果]1.研究組與對照組之間MMSE量表、ADL量表、ADAS-cog量表評分、血清PGRN蛋白濃度兩兩比較,研究組與對照組量表總分(P0.05),兩兩比較后發(fā)現(xiàn)研究組各組間量表總分:P均大于0.05,研究組與對照組量表總分:P值均小于0.05。AD組血清PGRN蛋白濃度(13.69±1.99)ng/ml,VD組血清PGRN蛋白濃度(19.39±1.34)ng/ml,MD組血清PGRN蛋白濃度(18.38±1.05)ng/ml,對照組血清 PGRN 蛋白濃度(20.39±1.69)ng/ml。2.研究組與對照組血清PGRN蛋白濃度比較(F = 59.36,P0.01),差異有統(tǒng)計學(xué)意義,進一步進行兩兩比較,[(MD組)vs(AD組)](P0.05),[(VD組)vs(MD組)](P0.05),[(對照組)vs(VD組)](P0.05)。3.研究組血清PGRN蛋白與MMSE、ADL、ADAS-cog量表各分組評分及總分比較,P均大于0.05,進一步探討各個研究組血清PGRN蛋白濃度與量表分組及總分之間的相關(guān)性,各項P均0.05,但AD組MMSE量表中即刻回憶一項(P0.05,r=0.037),差異有統(tǒng)計學(xué)意義。[結(jié)論]1.研究各組間認知量表評分無明顯相關(guān),研究組量表評分及血清PGRN蛋白濃度顯著低于對照組。2.血清PGRN濃度:AD組MD組VD組對照組,血清PGRN蛋白可能參與AD、VD、MD發(fā)病。3.研究組血清PGRN蛋白與MMSE、ADL、ADAS-cog量表評分無關(guān),但可能與AD患者中即刻回憶一項有關(guān)。
[Abstract]:[Objective] Alzheimer's disease (AD), as a latent central neurodegenerative disease, has become a global research hotspot with the increasing number of the elderly population in China. Alzheimer's disease is a common type of Alzheimer's disease. Early identification, early diagnosis and intervention are particularly important for dementia patients. Progranulin (PGRN) has been shown to be associated with frontotemporal dementia, Alzheimer's disease, breast cancer, multiple sclerosis, and systemic disease in recent years. Lupus erythematosus and other diseases are related, but the effect of PGRN on human Alzheimer's disease is seldom studied. According to previous studies, some mechanisms of PGRN are related to the pathogenesis of Alzheimer's disease and vascular dementia, and PGRN can be expressed in peripheral blood through the blood-brain barrier. Serum PGRN levels were measured in several types of dementia patients, and MMSE and other cognitive related scales were evaluated to explore the correlation between the two. Serum PGRN levels were measured by enzyme-linked immunosorbent assay (ELISA). Memory and activity of daily living (ADL) were assessed by MMSE (Mini-mental state examination), ADAS-cog (Alzheimer's disease assessment scale cognitive section) and other scale s. Cognition was assessed. Statistical Package for Social Science (SPSS) software package was used to analyze the general statistical data and all the scale data. Variance analysis was used to compare the differences between the four scale scores and the serum PGRN protein concentration of the four groups. LSD-t method was used to further compare the four groups. The serum PGRN protein concentration and ADAS score, ADL score and MMSE score were analyzed by Pearson correlation analysis for the data conforming to normal distribution and spearson analysis for the data not conforming to normal distribution. Compared with the control group, the total score of each group was higher than 0.05, and the total score of the study group and the control group was lower than 0.05. The concentration of serum PGRN protein in AD group was 13.69 (+ 1.99) ng/ml, and the concentration of serum PGRN protein in VD group was 19.39 (+ 1.34) ng/ml, MD group was lower than that in MD group. Serum PGRN protein concentration (18.38 (1.05) ng/ml, control group serum PGRN protein concentration (20.39 (1.69) ng/ml.2. Study group and control group serum PGRN protein concentration (F = 59.36, P 0.01), the difference was statistically significant, further two comparisons, [(MD group) vs (AD group)] (P 0.05), [(VD group) vs (MD group)] (P 0.05), [(control group) vs (VD group)] (P 0.05)] (P 0.3. The serum PGRN protein and MMSE, ADL, ADAS-cog scales were more than 0.05 in each group, P was greater than 0.05, further explore the correlation between the serum PGRN protein concentration and the scale grouping and total score, P was 0.05, but the AD group MMSE scale immediately recall one item (P 0.05, r = 0.037), the difference was statistically significant. [Conclusion]1. There was no significant correlation between cognitive scale scores and serum PGRN concentration. 2. Serum PGRN concentration: AD group MD group VD control group, serum PGRN protein may participate in AD, VD, MD onset. 3. Study group serum PGRN protein and MMSE, ADL, ADAS-cog scale score is not related, but may be related to AD patients in the moment. Recall a related story.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R749.16
本文編號：2204156
[Abstract]:[Objective] Alzheimer's disease (AD), as a latent central neurodegenerative disease, has become a global research hotspot with the increasing number of the elderly population in China. Alzheimer's disease is a common type of Alzheimer's disease. Early identification, early diagnosis and intervention are particularly important for dementia patients. Progranulin (PGRN) has been shown to be associated with frontotemporal dementia, Alzheimer's disease, breast cancer, multiple sclerosis, and systemic disease in recent years. Lupus erythematosus and other diseases are related, but the effect of PGRN on human Alzheimer's disease is seldom studied. According to previous studies, some mechanisms of PGRN are related to the pathogenesis of Alzheimer's disease and vascular dementia, and PGRN can be expressed in peripheral blood through the blood-brain barrier. Serum PGRN levels were measured in several types of dementia patients, and MMSE and other cognitive related scales were evaluated to explore the correlation between the two. Serum PGRN levels were measured by enzyme-linked immunosorbent assay (ELISA). Memory and activity of daily living (ADL) were assessed by MMSE (Mini-mental state examination), ADAS-cog (Alzheimer's disease assessment scale cognitive section) and other scale s. Cognition was assessed. Statistical Package for Social Science (SPSS) software package was used to analyze the general statistical data and all the scale data. Variance analysis was used to compare the differences between the four scale scores and the serum PGRN protein concentration of the four groups. LSD-t method was used to further compare the four groups. The serum PGRN protein concentration and ADAS score, ADL score and MMSE score were analyzed by Pearson correlation analysis for the data conforming to normal distribution and spearson analysis for the data not conforming to normal distribution. Compared with the control group, the total score of each group was higher than 0.05, and the total score of the study group and the control group was lower than 0.05. The concentration of serum PGRN protein in AD group was 13.69 (+ 1.99) ng/ml, and the concentration of serum PGRN protein in VD group was 19.39 (+ 1.34) ng/ml, MD group was lower than that in MD group. Serum PGRN protein concentration (18.38 (1.05) ng/ml, control group serum PGRN protein concentration (20.39 (1.69) ng/ml.2. Study group and control group serum PGRN protein concentration (F = 59.36, P 0.01), the difference was statistically significant, further two comparisons, [(MD group) vs (AD group)] (P 0.05), [(VD group) vs (MD group)] (P 0.05), [(control group) vs (VD group)] (P 0.05)] (P 0.3. The serum PGRN protein and MMSE, ADL, ADAS-cog scales were more than 0.05 in each group, P was greater than 0.05, further explore the correlation between the serum PGRN protein concentration and the scale grouping and total score, P was 0.05, but the AD group MMSE scale immediately recall one item (P 0.05, r = 0.037), the difference was statistically significant. [Conclusion]1. There was no significant correlation between cognitive scale scores and serum PGRN concentration. 2. Serum PGRN concentration: AD group MD group VD control group, serum PGRN protein may participate in AD, VD, MD onset. 3. Study group serum PGRN protein and MMSE, ADL, ADAS-cog scale score is not related, but may be related to AD patients in the moment. Recall a related story.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R749.16
【參考文獻】
相關(guān)期刊論文 前10條
1 閆濤;;治療阿爾茨海默病的藥物研究進展[J];天津藥學(xué);2016年03期
2 單體臻;王新;王海峰;莊珊;邢成名;;血清MMP-2、MMP-9水平與阿爾茨海默病及輕度認知障礙關(guān)系的臨床研究[J];中國醫(yī)刊;2016年06期
3 齊倩倩;劉志娟;呂佩源;;血管性認知功能障礙危險因素的研究進展[J];疑難病雜志;2015年12期
4 王菲;;血管性癡呆的分子機制及治療學(xué)研究進展[J];中國神經(jīng)精神疾病雜志;2014年05期
5 Zhichun Chen;Chunjiu Zhong;;Oxidative stress in Alzheimer's disease[J];Neuroscience Bulletin;2014年02期
6 欒冰;許微微;王靳君;;老年癡呆癥發(fā)病機制及其藥物治療[J];中國藥物經(jīng)濟學(xué);2013年06期
7 曾瀛;徐麗君;唐震宇;鄧麗影;;阿爾茨海默病患者尿液中相關(guān)的神經(jīng)絲蛋白的診斷價值[J];中國老年學(xué)雜志;2013年13期
8 盧英紅;呂蘭海;羅利;李博斐;徐杰;;短暫性腦缺血再灌注對大鼠腦PGRN表達的影響[J];解剖學(xué)研究;2013年01期
9 張景燕;王蓉;趙靜姝;姬志娟;趙志煒;盛樹力;;APP5肽類似物P165和羅格列酮對SH-SY5Y細胞IRS-1和p-CREB表達的影響[J];首都醫(yī)科大學(xué)學(xué)報;2011年04期
10 沈偉,李海林 ,葉勤 ,吳瑞枝 ,陸蓉;阿爾茨海默病、阿爾茨海默病混合型及血管性癡呆患者心理及行為癥狀的比較[J];健康心理學(xué)雜志;2003年06期
相關(guān)會議論文 前1條
1 井華;譚夢姍;郁金泰;譚蘭;;顆粒蛋白前體參與阿爾茨海默病的作用研究[A];第四屆全國癡呆與認知障礙學(xué)術(shù)研討會及高級講授班論文匯編[C];2015年
，本文編號：2204156
本文鏈接：http://sikaile.net/yixuelunwen/jsb/2204156.html
最近更新
教材專著
